Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.
In the phase 2b FRONTIER 2 clinical trial (NCT05364554), JNJ-2113—the first and only investigational targeted oral peptide designed to block the interleukin-23 (IL-23) receptor to treat patients with plaque psoriasis—showed promising efficacy compared with the most commonly prescribed oral psoriasis drug on the market, said Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh. However, head-to-head trials are needed to draw efficacy comparisons between JNJ-2113 and other agents.
Transcript
Were there any notable adverse events or safety concerns observed during the trial, particularly over the 52-week treatment period?
One of the impressive things about this molecule was the lack of safety signals. So, we saw a safety profile that was pretty consistent with what we see with the IL-23 [interleukin-23] inhibitor biologics.
In this study, 59% of patients had 1 or more adverse events; that is pretty consistent with what we would expect over a year. The most commonly reported adverse events were upper respiratory infections, nasal pharyngitis, and COVID-19. There really were no safety signals that we're seeing, like inflammatory bowel disease or depression. There really weren't unusual infections. There were no sort of dose-dependent safety events, so there weren't things that we started to see more of, for example, in the higher dosing arms.
How do the response rates observed with JNJ-2113 compare with existing treatments for moderate to severe plaque psoriasis?
Comparing JNJ-2113 efficacy to some of the other drugs on the market; very importantly, we really can't compare across 2 different trials, we really should only compare things when we have a head-to-head study. But we can look at, for example, PASI 100 [Psoriasis Area Severity Index] responses. So, for this drug, JNJ-2113, 40% of patients had a PASI 100 response. If we look at Skyrizi [risankizumab-rzaa], which is an injectable biologic, that number is about 60%.
If we look at Otezla [apremilast], another oral agent which is on the market, we can look at PASI 75 responses there, and 33% of patients had a PASI 75 response on Otezla. So, we can see superior efficacy in this oral drug as compared to the most commonly prescribed oral drug for psoriasis in the market, currently.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More